Current Oncology, Free Full-Text

Background: Information on immune responses in cancer patients following mRNA COVID-19 vaccines is still insufficient, but generally, patients had impaired serological responses, especially those with hematological malignancies. We evaluated serological response to COVID-19 mRNA vaccine in cancer patients receiving chemotherapy compared with healthy controls. Methods: In total, 195 cancer patients and 400 randomly selected controls who had been administered a Pfizer-BioNTech or Moderna COVID-19 vaccines in two doses were compared. The threshold of positivity was 4.33 BAU/mL. Patients were receiving anticancer treatment after the first and second dose of the vaccines. Results: a TOTAL OF 169 patients (87%) had solid tumors and 26 hemolymphopoietic diseases. Seropositivity rate was lower in patients than controls (91% vs. 96%), with an age/gender-adjusted rate ratio (RR) of 0.95 (95% CL = 0.89–1.02). Positivity was found in 97% of solid cancers and in 50% of hemolymphopoietic tumors. Both advanced and adjuvant therapy seemed to slightly reduce seropositivity rates in patients when compared to controls (RR = 0.97, 95% CL = 0.89–1.06; RR = 0.94, 95% CL = 0.87–1.01). Conclusions: the response to vaccination is similar in patients affected by solid tumors to controls. On the contrary, hemolymphopietic patients show a much lower response than controls.

Home Page: Clinical Oncology

Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs - The Lancet Oncology

GU Oncology Now

The Lancet Oncology

Current Oncology An Open Access Journal from MDPI

Remission, cancer-free, no evidence of disease: What's the difference?

Free Oncology CE and CME for Healthcare Professionals

Home Page: Journal of Thoracic Oncology

Current Issue Table of Contents: Radiotherapy and Oncology

Artificial intelligence in oncology: current applications and future perspectives

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study - The Lancet Oncology